BCPyr
BCPyr (Pfizer cIAP1-based BTK degrader)
"compound 4j"
“compound 4j” (Janssen (JNJ) brain-penetrant in vivo 5-HT2 antagonist and 5-HT7 inverse agonist, backup candidate)
LY3502970
Chugai/Lilly clinical oral non-peptide GLP-1R GPCR partial agonist
S64315
Servier selective clinical Mcl-1 protein-protein interaction (PPI) inhibitor
BMS-986144
Bristol-Myers Squibb (BMS) pan-genotype HCV NS3/4A protease inhibitor
MLT-985
MLT-985 (Novartis allosteric MALT1 protease (paracaspase) inhibitor)
daridorexant
Idorsia clinical dual orexin receptor GPCR antagonist
"peptide 78"
Merck/UCB/Ra Pharma macrocyclic PCSK9 protein-protein interaction (PPI) inhibitor
OATD-01: An Oral, First-In-Class CHIT1/AMCase Chitinase Inhibitor
OATD-01 (OncoArendi Therapeutics oral, first-in-class CHIT1/AMCase chitinase inhibitor clinical candidate)
CC-90011: A Selective and Reversible LSD1 Inhibitor
CC-90011 (Celgene/Bristol Myers Squibb (BMS)) selective, reversible LSD1 inhibitor clinical candidate)
CG428: A CRBN-Based TRK Kinase Fusion Protein Degrader
CG428 (Cullgen CRBN-based TRK kinase fusion protein degrader)
Compound 34: An Oral PARP1-Selective Polymerase Inhibitor
“compound 34” (Lupid oral in vivo PARP1-selective polymerase inhibitor)
LEO 39652: A Novel “Dual-Soft” PDE4 Inhibitor
LEO 39652 (LEO Pharma “dual-soft” topical PDE4 inhibitor soft drug clinical candidate)
AG-636: A Dihydroorotate Dehydrogenase Inhibitor
AG-636 (Agios Pharmaceuticals dihydroorotate dehydrogenase (DHODH) inhibitor clinical candidate)
EST73502: A Dual µ-Opioid Receptor Agonist, σ1 Antagonist
“EST73502” (ESTEVE oral dual mu-opioid receptor agonist, sigma-1 receptor antagonist clinical candidate)
Compound 46: An Oral Brain-Penetrant PDE2A Phosphodiesterase Inhibitor
“compound 46” (Janssen oral selective brain-penetrant PDE2A phosphodiesterase inhibitor)
Compound 25: IRE1 Kinase-Binding Endonuclease Inhibitor
“compound 25” (Genentech IRE1 alpha kinase-binding endonuclease inhibitor)
"lipid 10a"
“lipid 10a” (Arcturus tunable lipid for RNA drug delivery)